BRPI0517795B8 - conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica - Google Patents

conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica

Info

Publication number
BRPI0517795B8
BRPI0517795B8 BRPI0517795A BRPI0517795A BRPI0517795B8 BR PI0517795 B8 BRPI0517795 B8 BR PI0517795B8 BR PI0517795 A BRPI0517795 A BR PI0517795A BR PI0517795 A BRPI0517795 A BR PI0517795A BR PI0517795 B8 BRPI0517795 B8 BR PI0517795B8
Authority
BR
Brazil
Prior art keywords
factor viii
site
procoagulant activity
preparation
methods
Prior art date
Application number
BRPI0517795A
Other languages
English (en)
Inventor
Mei Baisong
Q Pan Clark
Wang Deqian
Tjandra Hendri
Chen Jianmin
E Murphy John
S Strauss Jonathan
Tang Liang
Barnett Thomas
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517795(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Priority to BR122016022033A priority Critical patent/BR122016022033B8/pt
Publication of BRPI0517795A publication Critical patent/BRPI0517795A/pt
Publication of BRPI0517795A8 publication Critical patent/BRPI0517795A8/pt
Publication of BRPI0517795B1 publication Critical patent/BRPI0517795B1/pt
Publication of BRPI0517795B8 publication Critical patent/BRPI0517795B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

modificação sítio-dirigida de fviii. esta invenção se refere a muteinas de fator viii que são ligadas de modo covalente, em um sítio predefinido que não é uma amina de n-terminal, a um ou mais polímeros biocompatíveis tais como polietileno glicol. os conjugados de muteina conservam atividade pró-coagulante de eviii e têm propriedades fa rmacocinéticas aperfeiçoadas.
BRPI0517795A 2004-11-12 2005-11-14 conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica BRPI0517795B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016022033A BR122016022033B8 (pt) 2004-11-12 2005-11-14 conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
US60/627,277 2004-11-12
PCT/US2005/041205 WO2006053299A2 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (4)

Publication Number Publication Date
BRPI0517795A BRPI0517795A (pt) 2008-10-21
BRPI0517795A8 BRPI0517795A8 (pt) 2018-12-26
BRPI0517795B1 BRPI0517795B1 (pt) 2020-03-31
BRPI0517795B8 true BRPI0517795B8 (pt) 2021-05-25

Family

ID=36337298

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0517795A BRPI0517795B8 (pt) 2004-11-12 2005-11-14 conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica
BR122016022033A BR122016022033B8 (pt) 2004-11-12 2005-11-14 conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122016022033A BR122016022033B8 (pt) 2004-11-12 2005-11-14 conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica

Country Status (32)

Country Link
US (4) US7632921B2 (pt)
EP (9) EP3153181A1 (pt)
JP (5) JP2008524117A (pt)
KR (7) KR101654011B1 (pt)
CN (6) CN105148287B (pt)
AU (1) AU2005304622B2 (pt)
BR (2) BRPI0517795B8 (pt)
CA (1) CA2586379C (pt)
CY (3) CY1119292T1 (pt)
DK (3) DK2363414T3 (pt)
ES (4) ES2930159T3 (pt)
FR (1) FR19C1031I2 (pt)
HK (3) HK1117875A1 (pt)
HN (1) HN2007015683A (pt)
HR (2) HRP20180481B1 (pt)
HU (5) HUE059193T2 (pt)
IL (3) IL182903A (pt)
LT (5) LT3130601T (pt)
LU (1) LUC00118I2 (pt)
MA (1) MA29663B1 (pt)
MX (2) MX350293B (pt)
NL (1) NL300989I2 (pt)
NO (3) NO20210454A1 (pt)
NZ (1) NZ555032A (pt)
PH (2) PH12014500352B1 (pt)
PL (3) PL2363414T3 (pt)
PT (4) PT2363414T (pt)
RU (1) RU2423380C2 (pt)
SI (4) SI3130601T1 (pt)
UA (1) UA95225C2 (pt)
WO (1) WO2006053299A2 (pt)
ZA (1) ZA200703696B (pt)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP3153181A1 (en) 2004-11-12 2017-04-12 Bayer HealthCare LLC Site-directed modification of fviii bdd
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN104593348A (zh) * 2006-05-24 2015-05-06 诺沃—诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
JP2009544327A (ja) 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
CN103804489A (zh) 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
GB2467700A (en) 2007-11-09 2010-08-11 Baxter Int Modified recombinant Factor VIII and von Willebrand Factor and methods of use
CN101965200B (zh) * 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
CN102112144A (zh) 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
CA2726942A1 (en) * 2008-06-04 2009-12-10 Bayer Healthcare Llc Fviii muteins for treatment of von willebrand disease
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
PL2349342T3 (pl) * 2008-10-17 2019-01-31 Baxalta GmbH Zmodyfikowane czynniki krwi zawierające mały stopień polimeru rozpuszczalnego w wodzie
JP2012508172A (ja) * 2008-11-03 2012-04-05 バイエル・ヘルスケア・エルエルシー 血友病の治療方法
CA2744340A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
CA2748662A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
CN102333788A (zh) * 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
BRPI1013626B8 (pt) * 2009-03-20 2021-05-25 Hanmi Holdings Co Ltd método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
TWI537006B (zh) 2009-07-27 2016-06-11 巴克斯歐塔公司 凝血蛋白接合物
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
LT2506868T (lt) 2009-12-06 2018-02-26 Bioverativ Therapeutics Inc. Faktoriaus viii-fc chimeriniai ir hibridiniai polipeptidai ir jų panaudojimo būdai
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US20130040888A1 (en) 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
ES2769629T3 (es) * 2010-02-21 2020-06-26 Bayer Healthcare Llc Procedimiento de activación y conjugación de biomoléculas
KR102416359B1 (ko) 2010-04-15 2022-07-01 코디악 사이언시스 인코포레이티드 고분자량 쌍성이온-함유 중합체
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
SG190136A1 (en) 2010-11-05 2013-07-31 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
CN103282045A (zh) * 2010-12-16 2013-09-04 诺沃—诺迪斯克有限公司 因子viii水溶液
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
CA3012117A1 (en) * 2011-05-27 2012-12-06 Baxalta Incorporated Fusions of psa with serpins and other therapeutic proteins
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
BR112014000055A2 (pt) 2011-07-01 2017-06-13 Bayer Ip Gmbh polipeptídeos de fusão de relaxina e usos dos mesmos
CA2841066C (en) 2011-07-08 2023-09-26 Biogen Idec Hemophilia Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EP2758426B1 (en) 2011-09-23 2019-08-07 Novo Nordisk A/S Novel glucagon analogues
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
PL3564260T3 (pl) 2012-02-15 2023-03-06 Bioverativ Therapeutics Inc. Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania
AU2013204636B2 (en) 2012-02-15 2016-04-14 Bioverativ Therapeutics Inc. Recombinant Factor VIII proteins
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
RU2015144076A (ru) * 2013-03-15 2017-04-24 БАЙЕР ХелсКер ЛЛСи Композиции рекомбинантного фактора viii
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
AU2014255608B2 (en) 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3041513B1 (en) 2013-09-08 2020-08-05 Kodiak Sciences Inc. Factor viii zwitterionic polymer conjugates
EP3060242A1 (en) * 2013-10-22 2016-08-31 DBV Technologies Method of treating haemophilia by inducing tolerance to blood factors
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
CN106414491B (zh) 2014-01-20 2021-06-18 奥克塔法马股份有限公司 一种制备FVIII:C/FVIII:Ag比例提高的因子VIII的方法
KR20230136616A (ko) 2014-02-04 2023-09-26 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도
WO2015132724A1 (en) * 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
US11181534B2 (en) * 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
CA2945390A1 (en) 2014-04-10 2015-10-15 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
CA2953593C (en) 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US11155601B2 (en) 2015-03-06 2021-10-26 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
AU2016266627A1 (en) 2015-05-22 2018-01-18 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
AU2016267539B2 (en) 2015-05-22 2019-12-05 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
JP6851381B6 (ja) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 変異切断型フォンウィルブランド因子
WO2017117630A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated von willebrand factor
EP3476860A4 (en) * 2016-06-24 2020-01-22 Mogam Institute for Biomedical Research RECOMBINANT SINGLE CHAIN FVIII AND CHEMICAL CONJUGATE THEREOF
SG10201912768YA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
ES2869339T3 (es) 2016-11-11 2021-10-25 CSL Behring Lengnau AG Polipéptidos del factor von Willebrand truncados para el tratamiento de la hemofilia
PE20190966A1 (es) 2016-11-16 2019-07-08 Bayer Healthcare Llc Factor viii direccionado a los globulos rojos y metodo para su uso
AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
JP2020505424A (ja) 2017-01-31 2020-02-20 バイオベラティブ セラピューティクス インコーポレイテッド 因子ｉｘ融合タンパク質ならびにその製造および使用方法
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
JP2023505208A (ja) * 2019-12-06 2023-02-08 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子の機能を調節するための組成物および方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1994015625A1 (en) * 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
EP0730660A4 (en) 1993-10-29 1998-02-25 Incyte Pharma Inc CHIMEAN PROTEINE PROTEASE NEXIN-1 CONTAINING VARIANTS
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
EP0776530A4 (en) * 1995-06-21 1998-06-10 Motorola Inc METHOD AND ANTENNA PRODUCING AN OMNIDIRECTIONAL RADIATION DIAGRAM
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
EP0964702B1 (en) * 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2306629A1 (en) * 1997-10-17 1999-04-29 Harvest Technologies Corporation Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
WO1999055306A1 (en) 1998-04-27 1999-11-04 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1129186B2 (de) 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
EP2305804B1 (en) * 1999-01-14 2015-05-06 Bolder Biotechnology, Inc. MonoPEGylated human growth hormone
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
ATE428445T1 (de) * 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
CA2434097A1 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
EP1373493B1 (en) * 2001-03-22 2013-07-31 Novo Nordisk Health Care AG Coagulation factor vii derivative
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
DE60234193D1 (de) 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
JP4634036B2 (ja) 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
CN1646564A (zh) 2002-04-18 2005-07-27 默克专利有限公司 修饰的因子ⅷ
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
AU2003300139B2 (en) 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
MXPA05007348A (es) 2003-01-06 2005-10-05 Nektar Therapeutics Al Corp Derivados de polimeros solubles en agua tiol-selectivos.
EP2572732A1 (en) * 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
MXPA05012315A (es) 2003-05-12 2006-04-18 Affymax Inc Compuestos poli(etilenglicol) modificados novedosos y usos de los mismos.
NZ541374A (en) 2003-05-23 2008-09-26 Nektar Therapeutics Al Corp PEG derivatives having an amidocarbonate linkage
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1682106A4 (en) 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII FACTOR WITH REDUCED IMMUNOGENICITY THROUGH MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (en) 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
EP3153181A1 (en) 2004-11-12 2017-04-12 Bayer HealthCare LLC Site-directed modification of fviii bdd
WO2006103298A2 (en) 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ

Also Published As

Publication number Publication date
CN101124331A (zh) 2008-02-13
HUS1900026I1 (hu) 2022-04-28
EP1824988B1 (en) 2017-04-19
FR19C1031I1 (pt) 2019-06-28
JP6559642B2 (ja) 2019-08-14
EP1824988A2 (en) 2007-08-29
HK1218718A1 (zh) 2017-03-10
JP2013067621A (ja) 2013-04-18
NO20072997L (no) 2007-06-27
KR20140019489A (ko) 2014-02-14
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
MX2007005466A (es) 2007-10-19
EP2371856A2 (en) 2011-10-05
KR20130036780A (ko) 2013-04-12
DK1824988T3 (en) 2017-08-07
CA2586379A1 (en) 2006-05-18
MA29663B1 (fr) 2008-08-01
CN105148287A (zh) 2015-12-16
EP2363414A3 (en) 2012-03-21
PL1824988T3 (pl) 2018-01-31
EP2371856B1 (en) 2022-05-18
BR122016022033B1 (pt) 2021-03-02
NO345800B1 (no) 2021-08-09
PH12014500352A1 (en) 2015-07-20
PH12014500352B1 (en) 2015-07-20
LTC1824988I2 (lt) 2021-02-25
EP3243833B1 (en) 2020-06-17
NO344606B1 (no) 2020-02-10
JP6109523B2 (ja) 2017-04-05
CY1119292T1 (el) 2018-02-14
HK1182121A1 (en) 2013-11-22
KR101654011B1 (ko) 2016-09-05
US20060115876A1 (en) 2006-06-01
EP2772500A1 (en) 2014-09-03
AU2005304622B2 (en) 2012-03-29
PL2363414T3 (pl) 2022-09-05
HUE060016T2 (hu) 2023-01-28
EP3323829B1 (en) 2020-07-15
US20160051633A1 (en) 2016-02-25
ES2633916T3 (es) 2017-09-26
ES2930159T3 (es) 2022-12-07
KR101243564B1 (ko) 2013-03-27
PT2363414T (pt) 2022-08-04
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
IL234433B (en) 2019-11-28
CN105148287B (zh) 2019-07-09
EP3243833A1 (en) 2017-11-15
PT3130601T (pt) 2020-10-01
DK2363414T3 (da) 2022-08-08
ZA200703696B (en) 2008-08-27
KR20180110192A (ko) 2018-10-08
EP2363414A2 (en) 2011-09-07
ES2930143T3 (es) 2022-12-07
HUE033776T2 (en) 2018-01-29
IL232540A (en) 2017-08-31
CN103102406A (zh) 2013-05-15
EP3153181A1 (en) 2017-04-12
RU2423380C2 (ru) 2011-07-10
EP3130601A1 (en) 2017-02-15
WO2006053299A3 (en) 2006-08-24
EP3130601B1 (en) 2020-07-15
CN105753968A (zh) 2016-07-13
IL232540A0 (en) 2014-06-30
EP2363414B1 (en) 2022-05-18
PL2371856T3 (pl) 2022-08-22
CN103214569A (zh) 2013-07-24
HRP20070268B1 (hr) 2018-04-20
HRP20070268A2 (en) 2007-09-30
PH12019501613A1 (en) 2020-09-14
LT2371856T (lt) 2022-08-25
HK1117875A1 (en) 2009-01-23
HRP20180481B1 (hr) 2022-02-18
US20100081615A1 (en) 2010-04-01
EP2772500B1 (en) 2019-12-25
CN107082806A (zh) 2017-08-22
DK2371856T3 (en) 2022-08-08
IL182903A0 (en) 2007-08-19
AU2005304622A1 (en) 2006-05-18
MX350293B (es) 2017-09-04
SI2371856T1 (sl) 2022-09-30
LT3130601T (lt) 2020-09-10
NL300989I1 (nl) 2019-05-22
JP2017105773A (ja) 2017-06-15
NL300989I2 (nl) 2019-11-28
PT1824988T (pt) 2017-07-21
LTPA2019509I1 (lt) 2019-08-26
IL182903A (en) 2014-09-30
LUC00118I1 (pt) 2019-05-13
UA95225C2 (ru) 2011-07-25
CY2019024I1 (el) 2019-11-27
CN103102406B (zh) 2015-05-27
ES2821832T3 (es) 2021-04-27
JP6487895B2 (ja) 2019-03-20
LT1824988T (lt) 2017-10-25
US9364520B2 (en) 2016-06-14
CN101124331B (zh) 2013-04-24
JP2008524117A (ja) 2008-07-10
HN2007015683A (es) 2011-07-11
EP3243834A1 (en) 2017-11-15
BRPI0517795A8 (pt) 2018-12-26
KR20120136413A (ko) 2012-12-18
BRPI0517795A (pt) 2008-10-21
JP2015134780A (ja) 2015-07-27
BR122016022033B8 (pt) 2021-05-25
EP1824988A4 (en) 2008-12-31
FR19C1031I2 (fr) 2020-06-05
NZ555032A (en) 2010-02-26
HRP20180481A2 (hr) 2018-06-29
HUE050542T2 (hu) 2020-12-28
US9096656B2 (en) 2015-08-04
BRPI0517795B1 (pt) 2020-03-31
PT2371856T (pt) 2022-08-12
EP2371856A3 (en) 2012-03-14
KR101483917B1 (ko) 2015-01-16
CY1123384T1 (el) 2021-12-31
CA2586379C (en) 2012-04-03
CY2019024I2 (el) 2019-11-27
KR20140091618A (ko) 2014-07-21
HUE059193T2 (hu) 2022-10-28
SI1824988T1 (sl) 2017-11-30
KR101468345B1 (ko) 2014-12-03
SI3130601T1 (sl) 2020-11-30
JP2017101028A (ja) 2017-06-08
KR20160105928A (ko) 2016-09-07
CN103214569B (zh) 2016-12-28
LT2363414T (lt) 2022-10-25
US20130274445A1 (en) 2013-10-17
EP3323829A1 (en) 2018-05-23
LUC00118I2 (pt) 2019-12-27
KR101904630B1 (ko) 2018-10-04
WO2006053299A2 (en) 2006-05-18
US7632921B2 (en) 2009-12-15
NO20200044A1 (no) 2007-06-27
RU2007121517A (ru) 2008-12-20

Similar Documents

Publication Publication Date Title
BRPI0517795B8 (pt) conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica
BRPI0411172A (pt) peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
BRPI0912411A8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
BRPI0721259C1 (pt) composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto
MX368966B (es) Conjugados de proteina-polimero-farmaco.
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
ECSP034765A (es) Derivados de bipiperidinilo y su uso como inhibidores de receptores de quimiocina
BRPI0507653A (pt) derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso
CY1109787T1 (el) Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
MY160922A (en) Polyethylene glycol conjugated blood coagulation factor vii
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
ATE442864T1 (de) Pharmazeutische zusammensetzung mit einem organopolysiloxan-elastomer und einem lösungsmittel-aktivwirkstoff
BR112023005789A2 (pt) Composição farmacêutica compreendendo conjugado anticorpo-fármaco e uso de composição farmacêutica
CY1106617T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα συμπλοκο ψευδαργυρου-υαλουρονικου για τη θεραπεια σκληρυνσης κατα πλακας
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
ITMI20041231A1 (it) Antagonisti del recettore dei vanilloidi trpv1
MY181129A (en) Site-directed modification of fviii
MY173864A (en) Site-directed modification of fviii
MY151329A (en) Site-directed modification of fviii
BR0109885A (pt) Moléculas duais, processo de preparação das mesmas, composições farmacêuticas, e, utilização das moléculas duais

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF